Marinus Pharmaceuticals’ (MRNS) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday, Benzinga reports. The firm currently has a $10.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on MRNS. HC Wainwright restated a buy rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a buy rating to a neutral rating in a research report on Wednesday, August 14th. Truist Financial reiterated a buy rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Oppenheimer raised Marinus Pharmaceuticals from a market perform rating to an outperform rating and set a $6.00 target price on the stock in a research note on Monday. Finally, StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $8.83.

Marinus Pharmaceuticals Stock Performance

NASDAQ:MRNS opened at $1.74 on Monday. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. The stock has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $2.67. The firm has a market capitalization of $95.84 million, a PE ratio of -0.66 and a beta of 1.13. Marinus Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same period in the prior year, the company posted ($0.61) earnings per share. Analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals in the second quarter worth $34,000. AQR Capital Management LLC raised its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals during the second quarter valued at $64,000. Finally, Values First Advisors Inc. grew its stake in shares of Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.